VINC vs. LPCN, ENLV, EQ, CDIO, FBRX, BCAB, ATHE, LVTX, MRKR, and PLUR
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Lipocine (LPCN), Enlivex Therapeutics (ENLV), Equillium (EQ), Cardio Diagnostics (CDIO), Forte Biosciences (FBRX), BioAtla (BCAB), Alterity Therapeutics (ATHE), LAVA Therapeutics (LVTX), Marker Therapeutics (MRKR), and Pluri (PLUR). These companies are all part of the "pharmaceutical products" industry.
Vincerx Pharma vs.
Lipocine (NASDAQ:LPCN) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, community ranking, media sentiment, dividends, profitability and analyst recommendations.
Lipocine's return on equity of -19.17% beat Vincerx Pharma's return on equity.
9.1% of Lipocine shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 6.1% of Lipocine shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Lipocine has higher revenue and earnings than Vincerx Pharma. Lipocine is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.
Lipocine currently has a consensus price target of $10.00, suggesting a potential upside of 128.83%. Vincerx Pharma has a consensus price target of $2.00, suggesting a potential upside of 1,213.20%. Given Vincerx Pharma's higher possible upside, analysts clearly believe Vincerx Pharma is more favorable than Lipocine.
Lipocine received 326 more outperform votes than Vincerx Pharma when rated by MarketBeat users. Likewise, 68.71% of users gave Lipocine an outperform vote while only 65.63% of users gave Vincerx Pharma an outperform vote.
In the previous week, Lipocine and Lipocine both had 1 articles in the media. Lipocine's average media sentiment score of 0.50 beat Vincerx Pharma's score of -0.50 indicating that Lipocine is being referred to more favorably in the media.
Lipocine has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.
Summary
Lipocine beats Vincerx Pharma on 8 of the 14 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:VINC) was last updated on 1/20/2025 by MarketBeat.com Staff
Free VINC Stock Alerts